Related Experiment Video
Updated: May 21, 2025
10:58
Transposon Mediated Integration of Plasmid DNA into the Subventricular Zone of Neonatal Mice to Generate Novel Models of Glioblastoma
Published on: February 22, 2015
12.9K
Targeting processive transcription for Myc-driven circuitry in medulloblastoma
Biorxiv : the Preprint Server for Biology
|April 1, 2025
Summary
CDK9 inhibition is a promising new strategy for treating Myc-amplified medulloblastoma (Myc-MB), a high-risk childhood brain tumor. Targeting CDK9 disrupts key cancer-driving programs, offering a potential new therapy for patients with poor outcomes.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Medulloblastoma (MB) is the most common malignant pediatric brain tumor.
- High-risk MB subtypes, driven by Myc amplifications (Myc-MB), have poor prognoses despite aggressive treatment.
- Myc oncogene drives pro-survival pathways, but direct targeting is challenging.
Purpose of the Study:
- To identify conserved dependencies in Myc-MB using pooled CRISPR-Cas9 screens.
- To investigate the therapeutic potential of inhibiting transcriptional cofactors, specifically CDK9, in Myc-MB.
Main Methods:
- Pooled CRISPR-Cas9 screening across multiple independent laboratories to identify genetic dependencies.
- Chromatin conformation capture (Hi-C) on primary patient Myc-MB samples to map enhancer-promoter interactions.
- Treatment of *in vitro* and xenograft models with CDK9/7 inhibitors to assess effects on Myc-driven programs and tumor growth.
Main Results:
- Eight independent CRISPR-Cas9 screens consistently identified CDK9 as a critical dependency in Myc-MB.
- CDK9 inhibition, especially when combined with CDK7 inhibition, demonstrated synergistic anti-tumor effects.
- Inhibition of CDK9/7 disrupted enhancer-promoter activity and downregulated Myc-driven transcriptional programs, leading to potent anti-tumor activity.
Conclusions:
- CDK9 is an essential cofactor for Myc-driven medulloblastoma.
- Dual CDK9/7 inhibition effectively targets the oncogenic transcriptional circuitry in Myc-MB.
- CDK9 inhibitors represent a promising therapeutic strategy for clinical development in Myc-MB.
More Related Videos
Related Concept Videos
01:06Induced Pluripotent Stem Cells
3.9K
Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
Somatic...
3.9K
02:23Master Transcription Regulators
6.8K
Master transcription regulators are regulatory proteins that are predominantly responsible for regulating the expression of multiple genes. Often these genes work in concert to drive a complex process. Activation of a master transcription regulator can lead to a cascade of transcriptional activation necessary for that outcome. These regulators can directly bind to the regulatory sequences of the various genes involved, or they can indirectly regulate transcription by binding to regulatory...
6.8K
02:23Abnormal Proliferation
4.4K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.4K
01:29Somatic to iPS Cell Reprogramming
2.2K
Reprogramming alters the gene expression in somatic cells, transforming them into induced pluripotent stem (iPS) cells over several generations. Scientists can reprogram cells by introducing genes for four transcription factors—Oct4, Sox2, Klf4, and c-Myc (OSKM) by viral or non-viral methods. These factors are also known as Yamanaka factors after Shinya Yamanaka, who first generated iPS cells using mouse skin cells. Yamanaka was awarded the Nobel Prize in Physiology or Medicine in 2012...
2.2K
03:03mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K